Charles Hoyng retired from the partnership in December 2015. Dr. Hoyng worked in Latham & Watkins’ Boston and Silicon Valley offices and a member of the Life Sciences, Emerging Companies, and Intellectual Property and Technology Practice Groups. Dr. Hoyng's prior practice consisted of negotiating and drafting life sciences technology license agreements and other similar agreements, and counseling in the development, protection, manufacture and distribution of products, particularly in the areas of:
-
Biotechnology
-
Pharmaceutical products
-
Medical diagnostic products
-
Medical devices
-
Healthcare related businesses
After earning his Ph.D. and prior to earning his law degree, Dr. Hoyng was a post-doctoral research fellow at the California Institute of Technology, Pasadena, California, an Assistant Professor of Chemistry at Texas A&M University, and held several positions at Genentech, Inc., including Director, Organic Chemistry, and Project Director for Genentech's tissue plasminogen activator (t-PA) project.
In addition to the bar qualifications listed above, Dr. Hoyng was licensed to practice law in the Northern District of California and the Court of Appeals, Ninth Circuit. At the time of his retirement, Dr. Hoyng was a member of the American Bar Association.
Dr. Hoyng was recognized:
-
As one of the leading life sciences attorneys in the world by Chambers USA (2008 through 2011)
-
In The International Who’s Who of Business Lawyers 2009 guide
-
As a "recommended lawyer" for licensing transactions by Intellectual Asset Management (IAM), 2012
-
As a "Life Sciences Star" for transactional work by LMG (Legal Media Group) Life Sciences, 2012
-
As a "Super Lawyer" in intellectual property by Super Lawyers, Thomson Reuters, 2004, 2005, 2012
Speaking Engagements and Publications
Dr. Hoyng has lectured frequently and is the author of several articles on topics related to his practice. Representative speaking engagements include:
- “Worldwide Company-University Collaborations," panelist at LESI 2012, Auckland, New Zealand, 2012
- "M&A/Dealmaking – Is M&A and Licensing Good for the Biotech Industry?" panel moderator, at Bio InvestorForum 2006, San Francisco, California, 2006
- "Pharmaceutical Co-Promotion and Co-Marketing Agreements in the US and Europe from a Biotech Perspective," panel moderator, at BayBio 2006: Accelerating Global Leadership, San Mateo, California, 2006
- “Intellectual Property and Licensing,” at the New Jersey Stem Cell Research Economic Summit, New Jersey Stem Cell Research Endowment Fund, Newark, New Jersey, 2004
- “Strategic Partnering and Licensing of Technology,” at International Biotechnology, M&A and Strategic Alliance, Tokyo, Japan, 2003
- “Strategic Partnering” at Merrill Lynch Asia Pacific Biotechnology Seminar, Roadmap for an Initial Public Offering, Singapore, 2003
- Practical Considerations in Licensing to and from Japanese Parties, The Journal of Proprietary Rights, Vol. 8, No. 6, June 1996